News
Altamira Therapeutics receives FDA acceptance for Bentrio 510(k) application.
Altamira Therapeutics Ltd. announced that its 510(k) application for premarket clearance filed with the FDA for its Bentrio nasal spray for protection against airborne allergens has cleared the Agency's acceptance review. The application now moves to a substantive review by the FDA.
Condition: Allergic Rhinitis
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins